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Abstract 
Validation of a Pressure Pain Threshold Scale in Patients Diagnosed  
with Myofascial Pain Syndrome and Fibromyalgia 
 
Background: Palpation is an examination technique used to diagnose and treat myofascial pain 
syndrome (MPS) and fibromyalgia (FM). Currently, there is no validated technique for 
classifying the results.  A valid and reliable pressure pain threshold scale (PPTS) may provide a 
means for clinicians to grade, document, and report findings. The purpose of this dissertation 
was to validate a PPTS in patients diagnosed with MPS and FM. Design and Methods:  An 
observational study. Participants who met the inclusion criteria were placed into three equal 
groups: MPS, FM, and control. All participants underwent one, two-part testing sessions using 
the American College of Rheumatology criteria. Part-I consisted of palpation with a digital 
pressure sensor and part-II utilized an algometer. For each tender point (18-total), the 
participants graded their level of discomfort using the visual analog scale (VAS) and manual 
tender point rating survey (MTPS) and the examiner graded their response using the PPTS (e.g. 
ordinal scale with increasing severity from 0-4). Analysis: Intrarater reliability was calculated 
using the intraclass correlation coefficient model 3, k. Concurrent validity between the PPTS, 
VAS, and MTPS was calculated using the spearman rank correlation coefficient. A receiver 
operating characteristic curve was used to determine the minimal cut-off value between groups. 
Results: Eighty-four participants were included in the analysis. The PPTS had good intrarater 
reliability (ICC ≥.88). A moderate to excellent relationship was found between the PPTS and 
VAS for all groups with the algometer and digital pressure sensor (rho ≥.61). A moderate to 
excellent relationship was found between the PPTS and MTPS for all groups with the algometer 
(rho≥.68) and for the MPS and control group with the digital pressure sensor (rho ≥.71). There 
was a little to moderate relationship (rho=.01-.50) between the PPTS and MTPS for the FM 
group with the digital pressure sensor. A cut-off value of 2 on the PPTS differentiated 
  
participants with MPS and FM from controls. Discussion: The results provide preliminary 
evidence validating the PPTS for patients with MPS and FM. Future research should determine 
interrater reliability, diagnostic accuracy, and efficacy of the PPTS with other chronic pain and 
orthopedic conditions.  
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Chapter 1 
 
1.0 Overview 
 Manual pressure palpation is a clinical examination technique used by physical therapists 
to examine and treat chronic musculoskeletal pathologies such as myofascial pain syndrome 
(MPS) and fibromyalgia (FM). This technique is taught in physical therapy education programs 
as part of the musculoskeletal clinical examination.1,2 Despite the expected standard of teaching 
palpation, there is lack of agreement for objectively and reliably measuring the technique, 
magnitude of pressure, minimal pain threshold, and patient reactivity level. This creates a gap in 
communication among clinicians and challenges the efficacy of this examination technique.  
Based upon the paucity of evidence, a more accurate assessment of this technique is 
necessary for clinical practice and research. One way of objectifying manual palpation is through 
the use of a valid and reliable pressure pain threshold scale (PPTS) that provides a method to 
measure and communicate the procedures for clinicians and researchers. This chapter will 
present the need for validating a PPTS and the purpose of the investigation. The specific research 
questions, relevance, significance, and practical application of this investigation will also be 
discussed.   
1.1 Problem Statement  
Palpation of bony structures and soft-tissue for tenderness (pain provocation) is 
performed by clinicians to assess the presence of a musculoskeletal pathology, differentiate 
tissues at fault as well as a means to postulate reactivity level, and severity of pathology.3 
Currently, there is no consensus on an objective and reliable method of grading manual pressure 
palpation despite what is taught in physical therapy education programs and defined in the Guide 
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to Physical Therapist Practice.2,4 The challenge lies in the subjective nature of palpation among 
clinicians which includes: 1) the amount of digital pressure to apply, 2) methods used to quantify 
or rank patient responses, and 3) interpretation of findings. This lack of consensus is problematic 
since palpation is part of the examination process for many musculoskeletal pathologies and is 
often used in clinical practice as a means of documenting change.   
 A valid and reliable PPTS is essential to the examination and diagnosis of 
musculoskeletal pathology. In particular, chronic pain conditions such as MPS and FM are 
dependent upon the findings from manual pressure palpation of tender points and trigger points 
(TrPs) since medical tests and imaging are inconclusive.5,6 It is estimated that up to 54% of 
women and 45% of men may suffer from MPS with the most common age range between 27 to 
50 years.7-9 It is also estimated that more than 5 million Americans have FM with a higher 
presence among women ages 35-60 years.3,10 In a 2012 study, Gaskin et al11 estimated the total 
cost for treating chronic pain conditions in the United States was between $560 to $635 million 
dollars. Several researchers have found that patients with chronic pain conditions incur higher 
annual healthcare costs when compared to matched controls.12-14 Despite the routine use of 
palpation in diagnosing MPS and FM, there is a lack of consensus regarding a standardized 
method of assessment and interpretation of findings. Wolf et al15 and Okifuji et al16 were the first 
researchers to use a manual pressure palpation protocol that included a rating scale for manual 
digital pressure with patients diagnosed with FM. The aforementioned authors did not report any 
validation or clinimetric data for the scales. These protocols have lacked further study since their 
original publication in the 1990’s. Currently, no studies exist that have validated a PPTS. 
The lack of consensus for measuring, documenting, and communicating manual pressure 
palpation for patients with MPS and FM creates a weakness in the standard physical therapy 
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examination when compared to other testing procedures such as goniometry which has been 
standardized based on procedures and normative values.17,18 Many clinicians’ routinely use 
minimal to moderate graded pressure with no standardized method. Thus, it is imperative that a 
valid and reliable scale is created since palpation is a standard component of the examination 
process.    
1.2 Research Purpose 
To date, there are no valid and reliable pressure pain threshold scales for use in research 
or clinical practice. The existing manual palpation protocols and scales have limited support in 
the literature and our knowledge has not advanced since these scales were proposed in the 
1990’s.15,16 Therefore, the purpose of this investigation was to develop a valid and reliable PPTS 
in order to provide an objective means of assessing pressure pain thresholds and create a reliable 
method of communication among clinicians for individuals with a diagnoses characterized by 
MPS and FM.  These conditions were chosen based on their high prevalence among chronic pain 
conditions and are also dependent upon the manual palpation examination for their diagnosis.   
1.3 Research Questions  
The purpose for this investigation was to validate a new PPTS in patients diagnosed with 
MPS and FM. This investigation included five research questions outlined below:  
Q1: What is the intrarater reliability of a 5-point PPTS in participants with MPS, FM, and 
healthy individuals (control group)?  
 Research Hypothesis (H1): There will be good intrarater reliability (ICC >.75) using 
the 5-point PPTS in participants with MPS, FM, and healthy individuals  
 
 Null Hypothesis (H01): There will not be good intrarater reliability (ICC >.75) using the 
5-point PPTS in participants with MPS, FM, and healthy individuals 
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Q2: Does a 5-point PPTS possess concurrent validity when compared to a 10cm (100mm) 
visual analog pain scale at 18 predetermined tender points in participants with MPS and FM?  
 Research Hypothesis (H2): The 5-point PPTS will have a moderate to excellent 
relationship (rho ≥ .50) with the 10cm visual analog scale at 18 predetermined tender 
points in participants with MPS and FM  
 
 Null Hypothesis (H02): The 5-point PPTS will not have a moderate to excellent 
relationship (rho ≥ .50) with the 10cm visual analog scale at 18 predetermined tender 
points in participants with MPS and FM.  
 
Q3: Does a 5-point PPTS possess concurrent validity when compared to a manual tender point 
survey scale at 18 predetermined tender points in participants with MPS and FM?  
 Research Hypothesis (H3): The 5-point PPTS will have a moderate to excellent 
relationship (rho ≥ .50) with the manual tender point survey scale at 18 predetermined 
tender points in participants with MPS and FM 
 Null Hypothesis (H03): The 5-point PPTS will not have a moderate to excellent 
relationship (rho ≥ .50) with the manual tender point survey scale at 18 predetermined 
tender points in participants with MPS and FM. 
Q4: Does manual palpation pressure up to 4 kg/cm2 measured by the Tekscan® Wireless ELF™ 
pressure sensor at 18 predetermined tender points produce a comparable response by the 
participant as algometry pressure up to 4 kg/cm2 using the 5-point PPTS in participants with 
MPS, FM, and in healthy individuals (control group)?  
 Research Hypothesis (H4): The Tekscan® Wireless ELF™ pressure sensor will have a 
moderate to excellent relationship (rho ≥ .50) with the algometer when using the 5-
point PPTS at 18 predetermined tender points in participants with MPS and FM  
 
 Null Hypothesis (H04): The Tekscan® Wireless ELF™ pressure sensor will not have a 
moderate to excellent relationship (rho ≥ .50) with the algometer when using the 5-
point PPTS at 18 predetermined tender points in participants with MPS and FM 
 
Q5: What is the cut-off value that differentiates participants with MPS and FM (combined) and 
healthy individuals (control group) using the 5-point PPTS? 
 Research Hypothesis (H5): A cut-off value of 2 will be the minimal difference on the 
5-point PPTS that differentiates participants with MPS and FM and healthy individuals.  
 
 Null Hypothesis (H05): A cut-off value of 2 will not be the minimal difference on the 5-
point PPTS that differentiates participants with MPS and FM and healthy individuals.  
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1.4 Relevance and Significance  
Currently, there is no consensus on the assessment technique of manual pressure 
palpation despite what is taught in physical therapy education programs and what is defined in 
the Guide to Physical Therapy Practice.1,2,4 This lack of consensus is problematic since pressure 
palpation is a component of the examination process for many musculoskeletal pathologies. In 
particular, the diagnoses of MPS and FM are dependent upon the findings from manual pressure 
palpation of tender points and trigger points (TrPs). Often, the interpretation of pressure 
palpation is subjective resulting in variable results among clinicians since no standard reference 
has been established.  
Several systematic reviews examining the efficacy of manual pressure palpation for neck 
and back pain have found the overall reliability of manual palpation to be weak with no superior 
method established.19-21 The common limitations reported among systematic reviews is the 
methodological variability and lack of standardization among studies which has created a gap in 
our knowledge about the manual palpation examination.19-21 These results have created an 
unclear translation from research to clinical practice and the development of a reference standard 
for technique, amount of applied pressure, and interpretation of findings. Clinicians often adopt 
their own methods of manual palpation with no objective way of measuring, documenting, and 
communicating their findings. 
Clinicians and researchers may use instruments such as pressure algometry to quantify a 
patient’s pressure pain threshold.22,23 Algometry is a valid and reliable measure with a broad 
utility for research.24-27 Several different devices have been developed such as an algometer with 
wireless capability28,29 and a smaller digital pressure sensor that uses a pressure sensing film.30 
This type of technology has portability and provides concurrent measures of the rate and amount 
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of force that is applied during the examination. However, these instruments can be expensive and 
may not be practical in many clinical settings.     
Clinicians also tend to use patient related outcome measures (PROs) such as the numeric 
pain rating scale (NPRS) or visual analog scale (VAS) to measure and track a patient’s 
progress.31 The NPRS and VAS are commonly used in studies involving pressure pain thresholds 
using manual palpation and algometry.31-33 The subjective nature of the measures is an inherent 
weakness and is often influenced by the patient’s perception of pain which can change.34 Despite 
this limitation, the NPRS and VAS are common outcome measures used to document and 
communicate a patient’s pressure pain threshold. To date, clinicians do not have a means of 
independently and objectively measuring, documenting, and communicating their findings 
beyond the PROs and instruments such as algometry. 
Chronic pain conditions such as MPS and FM depend on the manual pressure palpation 
examination for diagnosis since other medical tests (e.g. blood test) and imaging are 
inconclusive.5,35 The primary clinical finding for all the aforementioned diagnoses is the patient’s 
subjective report of pain or tenderness to palpation, which can be influenced by the amount of 
force applied and accuracy of palpation. This creates a need for a valid and reliable tool to 
measure manual pressure palpation and provide a means of communication among clinicians. In 
the 1990’s, Wolf et al15 and Okifuji et al16 used a manual palpation protocol and scoring system 
in their research on FM. The scales were part of a larger diagnostic protocol for diagnosing FM 
patients; however, the scales clinimetric properties were never fully studied beyond the initial 
publications.  
Due to the lack of consensus and standardization in the manual palpation assessment of 
MPS and FM, a valid and reliable pressure pain threshold scale (PPTS) may provide a means for 
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clinicians to measure, document, and communicate their findings. The overall efficacy of the 
manual pressure palpation assessment will be enhanced with the combined use of the PPTS, 
VAS, NPRS, and algometry. Both the clinician and patient can independently measure their 
results which may provide a higher level of objectivity than the methods currently being used.   
1.5 Practical Application of Findings  
To date, there are no valid and reliable pressure palpation threshold scales that have been 
universally accepted among researchers and clinicians. The development of a new PPTS will 
provide an objective way for clinicians to measure, document, and communicate their findings. 
In particular, the PPTS scale will provide a means for clinicians and researchers to objectively 
assess conditions such as MPS and FM beyond the standard protocols in existence.15,16  The 
PPTS scale can be used as an outcome measure in research involving pressure pain thresholds 
using manual palpation and algometry.      
1.6 Scope of the Investigation 
 This investigation required a number of resources. Permission from 3 facilities was 
required to obtain the desired sample size. Data collection was conducted at California State 
University Dominguez Hills in Carson, CA, South Bay Orthopedic Specialists Medical Center in 
Torrance, CA, and Fibromyalgia of Huntington Beach in Huntington Beach, CA. The permission 
letters can be seen in Appendix B. 
 
1.7 Definition of Terms  
 
The following terms represent the nomenclature that was used throughout this dissertation. 
The definitions are as follows: 
1) Fibromyalgia (FM): A chronic widespread pain disorder that affects the joints, muscles, 
tendons, and soft-tissue of the body.36 
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2) Myofascial pain syndrome (MPS): A syndrome characterized by chronic pain that is caused 
by multiple trigger points and fascial constriction.10 
3) Myofascial trigger points (TrPs): A hyperirritable region in skeletal muscle associated with 
palpable nodules in taut bands of muscle fibers. TrPs are a hallmark sign of MPS.10 
4) Pain: An unpleasant sensation occurring in varying degrees of severity as a consequence of 
injury, disease, or emotional disorders.34 
5) Manual palpation: Manual examination of the soft-tissue structure by direct contact of the 
examiner by feeling with the hand or fingers.37 
6) Pressure algometry: A mechanical form of pain assessment using a pressure gauge attached 
to a rubber tipped plunger.38  
7) Pressure sensor: A computerized digital force sensors that measures the amount of pressure 
applied to the transducer film.39  
8) Pressure pain threshold (PPT): The amount of pressure that triggers a pain response.40 
9) Pressure pain threshold scale (PPTS): A numeric rating scale that ranks the amount of 
manual pressure that triggers a pain response. 
 
1.8 Summary  
 
In summary, a valid and reliable PPTS will provide clinicians and researchers with an 
objective means of assessing pressure pain thresholds. The existing protocols and scales were 
developed in the 1990’s and have not been further researched. There is a lack of knowledge 
regarding their validity, reliability, and clinimetric properties. This creates a weakness in the 
standard physical therapy examination due to the subjective nature of manual palpation. The 
diagnosis of chronic musculoskeletal pathologies such as MPS and FM are dependent upon 
findings from the manual pressure palpation examination.  Development of a valid and reliable 
PPTS is necessary to improve the clinical examination and provide a consistent method of 
measuring, documenting, and communication among clinicians and researchers.  
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Chapter 2  
2.0 Introduction  
Manual pressure palpation is part of the standard physical therapy examination and is 
often used to detect the presence of TrPs and tender points in myofascial pain syndrome (MPS) 
and fibromyalgia (FM).41 Despite the routine use of this technique there are few universally 
accepted protocols or objective scales used in clinical practice and research. Moreover, the scales 
that have been used lack known clinimetric properties. The purpose of this chapter is to review 
the literature on MPS and FM including the clinical presentation, prevalence, and diagnosis of 
these conditions. This chapter will also discuss pressure pain threshold (PPT) protocols, 
instrumentation, patient related outcome measures, and weaknesses in the manual palpation 
examination. Finally, the contribution of this dissertation to the current body of literature will be 
discussed.   
2.1 Defining Myofascial Pain Syndrome and Fibromyalgia 
Myofascial pain syndrome (MPS) and fibromyalgia (FM) are classified as chronic 
widespread pain conditions characterized by soft tissue tenderness, fatigue, anxiety, sleep 
disturbances, and depression.3  Researchers have found the presence of myofascial trigger points 
(TrPs) in both MPS and FM6,41,42 The growing prevalence and economic burden of these chronic 
pain conditions have stimulated more research over the past two decades resulting in a better 
understanding of their pathophysiology.43   
MPS is described as a chronic muscular pain disorder affecting one or more muscles that 
results in a cluster of symptoms such as: local and referred pain, decreased range of motion 
(ROM), muscle weakness, and autonomic signs and symptoms caused by TrPs.36,44 TrPs play a 
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central role in the pathophysiology and are defined as hyperirritable tender spots or nodules in 
discrete taut bands of muscle that can produce local or referred pain.36 Current theory suggests 
that TrPs may be caused by several potential mechanisms including: local ischemia, eccentric 
overload, and submaximal sustained or concentric contractions.36,45 TrPs are classified as being 
latent or active which is dependent upon their clinical presentation.46 Latent TrPs may not 
produce a referred pain upon palpation but may restrict movement or cause muscle weakness.46 
Active TrPs are tender upon palpation and may cause a referred pain pattern which is often 
describe as “diffuse” or “radiating”. Active TrPs may be a source of pain at rest. TrPs are 
different than tender points which elicits pain at the site of palpation.46 TrPs are a common 
clinical finding in individuals diagnosed with FM as well.47  
FM is characterized by chronic widespread musculoskeletal pain that primarily affects 
the joints, muscles, tendons, and soft-tissue.48 Traditionally, FM has been categorized as a 
rheumatic-like disorder with accompanying psychological factors such as anxiety and 
depression.5 More current hypotheses suggest that FM is caused by a neurochemical imbalance 
in the central nervous system that is associated with a heightened pain perception.5,43 Individuals 
diagnosed with FM often have the triad of primary symptoms: tender points, fatigue, and sleep 
disturbances.5,35 Patients may also present with other symptoms including but not limited to: 
depression, anxiety, cognitive difficulties (e.g. poor concentration), balance problems, irritable 
bowel syndrome, headaches, palpable tenderness, stiffness, tingling and numbness, as well as 
restless leg syndrome.49 The triad of symptoms are a hallmark clinical finding for this condition.  
In summary, MPS is a regional condition with specific TrPs that can refer pain while FM 
is characterized by chronic widespread pain and local tender points.50  Both have unique clinical 
presentations but do have one related symptom: the trigger point (Table 2.1). Researchers have 
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found that the FM local tender points may also be active TrPs.6,41,42 Thus, individuals with FM 
may develop TrPs at the tender point sites that can refer pain.42,50,51 This research suggests a 
connection between the two conditions in which individuals with FM may also suffer from MPS 
or vice versa. Some researchers have postulated that FM may be concomitantly present in over 
50% of patients diagnosed with MPS.52  
Table 2.1 Primary Symptoms of MPS and FM 42,53  
Myofascial Pain Syndrome Fibromyalgia 
 TrPs (local and referred pain) 
 Fatigue and weakness 
 Decreased ROM 
 Autonomic signs and symptoms 
 Tender points and TrPs  
 Fatigue and weakness 
 Sleep disturbances  
 
 
2.2 Prevalence and Economic Burden 
It is estimated that up to 54% of women and 45% of men may suffer from MPS with the 
most common age range between 27 to 50 years.7-9 It is also estimated that more that 5 million 
Americans have FM with a higher presence among women ages 35-60 years.3,10 FM is often 
underdiagnosed with 1 in 5 receiving an accurate diagnosis within an average of 5 years.54,55 
Both conditions are classified as chronic pain conditions which have a high economic burden for 
the U.S. The most recent U.S. statistics, from 2012, showed that the total cost for treating chronic 
pain disorders ranged between $560 to $635 million annually.11 
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2.3 Diagnosis of Myofascial Pain Syndrome 
The diagnosis of myofascial pain syndrome (MPS) is often established from findings 
gathered during the clinical examination. Pertinent information gathered from the patient 
regarding their symptoms may include: type, intensity, duration, frequency and location of the 
pain, aggravating, and alleviating factors.45 The clinical examination of TrPs may include the use 
of manual palpation pressure or pressure algometry to find the location and assess the pressure 
pain threshold of the identified region.56 TrPs are considered active if the local and referred pain 
reproduces the concordant symptoms and described as a familiar pain.57 The accuracy of TrPs 
assessment has been studied on a wide population including but not limited to: individuals 
diagnosed with whiplash58, chronic non-specific low back pain59, chronic headaches60, chronic 
mechanical neck pain61, temporomandibular joint disorders62, and lateral epicondylalgia.63 The 
standard TrPs diagnostic examination uses the recommended criteria established by Simon and 
Travell (Table 2.2).64,65 Figure 2.1 illustrates common trigger point sites along the posterior neck, 
shoulders, trunk, and pelvis. Despite the widespread use of the TrPs examination there has been 
no true standardization including the amount of pressure and interpretation of findings. In 2008, 
Myburgh et al 37 conducted a systematic review (1965-2007) analyzing the effectiveness of 
manual pressure palpation in identifying TrPs. They found that the methodological quality of the 
majority of the studies was poor due to non-applicable study objectives and unreliable statistical 
calculations. In 2009, Lucas et al 66 conducted a systematic review (1965-2009) to determine the 
evidence regarding reliability of manual pressure palpation in identifying TrPs. They found that 
reliability estimates varied widely between studies. The authors concluded that no study to date 
has reported the reliability of TrPs assessment according to the recommended criteria by Travell 
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and Simons.64 Other authors have found similar findings and have concluded that there is limited 
consensus among clinicians and researchers.45,67  
Table 2.2 Travell and Simons Examination Criteria 64  
1) The clinician manually palpates and finds a taut band of muscle with a nodule. 
2) Upon sustained palpation, the patient reports a painful sensation in an area consistent with 
the established referred pain pattern of the involved muscle. 
3) The clinician quickly rolls his/her fingers over taut band and observes the presence of a 
visible or palpable local twitch response. 
4) During palpation, the patient demonstrates a general pain response characterized by 
withdrawing from palpation, wincing, or verbalizing their discomfort. 
 
 
Figure 2.1 Trigger point sites along the posterior neck, shoulders, trunk, and pelvis.  
(Stock image license granted to Scott Cheatham) 
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2.4 Diagnosis of Fibromyalgia  
Clinicians commonly use a standard examination process that is based upon the 
American College of Rheumatology (ACR) criteria for classification of fibromyalgia (FM).15 
The 1990 ACR criteria for diagnosing individuals with FM includes: history of widespread 
musculoskeletal pain for at least 3 months, bilateral axial pain that affects areas above and below 
the waist, and 11 out of 18 tender points.68 The tender point examination includes assessing 18 
predetermined tender points along the neck, back, arms, and legs (Figure 2.2) using either 
manual pressure palpation or pressure algometry.69  
 
Figure 2.2 1990 American College of Rheumatology Tender Point Criteria  
(Stock image license granted to Scott Cheatham) 
 
In 1990, Wolfe et al15 utilized a five point ranked scale and graded pressure using manual 
pressure palpation and pressure algometry to help quantify the ACR tender point criteria for the 
classification of FM. The five-point ordinal scale used anchoring “words” that correspond to 
each level. The rankings were as follows: 0-no pain, 1- mild pain (complaint of pain without 
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grimace, flinch, or withdrawal), 2- moderate pain (complaint of pain plus grimace or flinch), 3- 
severe (complaint of pain plus marked flinch or withdrawal), 4- unbearable (patient is 
untouchable). They further classified the score of 1 as “mild or greater” and a score of 2 as 
“moderate or greater”. 15 The manual pressure palpation level was determined to be a maximum 
of 4kg/cm2 (kilogram-force per square centimeter) of pressure using the thumb or the first 2 or 3 
fingers (e.g. blanching of the nail). The force was applied at a rate of 1kg per second.15 To 
establish reliability prior to data collection, investigators practiced the protocol and applied 
pressure to an algometer to quantify the amount of pressure palpation and rate of application to 
be used during the study. No reliability values were reported. Sixteen investigators participated 
in the data collection phase of the study. During data collection, the investigators tested 24 tender 
points and 6 control points along the body using this protocol for both palpation and algometry. 
Upon completion of the investigation, the authors established 18 pre-determined tender points 
with 11 of 18 being the minimum score for a classification of FM. The authors found that both 
manual palpation and algometry yielded a sensitivity of 88.4% and specificity of 81.1% in a 
sample of 293 participants diagnosed with FM when compared to a control group of 265 
participants. The diagnostic classification of FM patients or control patients was based upon the 
clinical expertise of the primary investigator.15 The authors determined that the term “painful” 
must be stated by the patient in order for the tender point to be considered positive (score of 1 or 
more). The term “tender” was considered as non painful (score of 0).15 The authors omitted the 
5-point scale and control points from the final criteria. This study provided the evidence for what 
is currently the ACR standard examination protocol for diagnosing FM (Table 2.3).   
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Table 2.3 1990 ACR Examination Protocol for Diagnosing FM 15 
Patient Subjective Criteria Clinical Examination Protocol 
 Widespread musculoskeletal pain for at 
least 3 months 
 Bilateral axial pain that affects areas 
above and below the waist  
 
 Palpate with thumb or first 2 or 3 fingers 
 Apply a maximum of 4kg/cm2 of pressure at a 
rate of 1kg per second. 
 11 out of 18 predetermined tender points are 
discovered. 
 Examiner documents provocation level using 5 
point scoring system for each tender point. 
 The patient must report the term “painful” for 
a tender point to be considered positive.  
 
In 1992, Cott et al70 further assessed the validity and reliability of the ACR examination 
protocol against pressure algometry in subjects (N=15) diagnosed with FM. They found that the 
interrater agreement using the Kappa coefficient was .51 for manual palpation and .62 for 
algometry. The authors also found that the manual pressure palpation examination resulted in 
significantly more anatomical points being considered tender relative to algometry.70 Jacobs et 
al48 also found similar values in patients with FM.  
In 1997, Okifuji et al16 expanded the ACR examination protocol by adding a verbal 
eleven point numeric pain rating scale (NPRS) called the Manual Tender Point Survey (MTPS) 
scale. The MTPS is a 11-point ordinal scale with verbal descriptions used as anchor points (0=no 
pain and 10=worst pain ever experienced). The authors found that a reported pain severity score 
of 2/10 (sensitivity 88.57%, specificity 71.43%) was an optimal point for identifying a tender 
point in 70 subjects with FM when compared to a control group.16  
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Weakness in the ACR criteria and Wolf scale  
The scale utilized by Wolf et al15 was the first attempt at establishing a universally 
accepted pressure pain scale. The scale was part of larger diagnostic protocol and the clinimetric 
properties were never fully studied. For example, the ACR examination depends on the patient 
stating the term “pain” in order to consider a tender point to be positive. Okifuji et al16 attempted 
to expand on the ACR criteria by adding a stricter protocol and the addition of the MTPS to 
quantify the patient’s level of sensitivity at each tender point. However, their protocol was never 
further researched.  
Later investigations began developing their own interpretation of the ACR tender point 
criteria and the Wolf scale. A study by Croft et al71 evaluated the relationship between tender 
points, complaints of pain, and symptoms of depression, fatigue, and sleep quality in the general 
population. They reported using the ACR criteria to classify individuals but modified the 
interpretation of a tender point. They excluded the Wolf scale and replaced the ACR criteria with 
a new tender point classification of “definite tenderness.” A positive tender point was considered 
the presence of any involuntary verbal or facial expression or a wince or withdrawal. Upon 
completion of the study, they determined that tender points are more a measure of distress rather 
than FM related pain.71 Other authors have modified their interpretation of the ACR criteria 
which has yielded variable outcomes and interpretations.72-76 The lack of standardization of 
scoring creates a weakness in the tender point exam and makes it a challenge to discriminate 
between individuals who have FM and the severity of the condition. Prescott et al77 and Croft et 
al72 found a correlation between the number of tender points and the type and severity of the pain 
in patients with FM. Thus, the non-standardized scoring and interpretation of tender points 
creates a weakness in the ACR examination process.  
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Emerging Criteria 
In 2010, Wolf et al78 conducted a preliminary investigation to modify the 1990 ACR 
examination protocol with the use of two questionnaires: Widespread Pain Index and the 
Symptom Severity Scale. These two questionnaires have been proposed by Wolfe et al to replace 
the traditional examination protocol. Preliminary data from Wolf et al78 suggests that these 
questionnaires successfully classified subjects with FM in 88.1% (N=730) of cases in a sample 
of 829 patients with a sensitivity of 96.6% and specificity was 91.8%. Other authors have 
assessed the modified criteria and have produced mixed results. Bidari et al79 found a lower 
sensitivity (58.9% versus 71.4%) in the 2010 modified criteria when compared to the 1990 
criteria in a sample of 168 subjects diagnosed with FM. Other authors have found the modified 
criteria to have similar levels of sensitivity and specificity as the 1990 ACR criteria.80-82 Due to 
mixed results, further studies are needed to validate these criteria. Currently, the 1990 ACR 
examination protocol is still the standard for diagnosing individuals with FM.82  
2.5 Dimensions of Chronic Pain 
Chronic pain is a multifaceted sensory and emotional experience that varies widely 
between individuals depending on the context and meaning of the pain and psychological state of 
the person.83 A combination of biological, psychological, and social factors interacts to influence 
pain.83 More specifically, cognitive and emotional factors have an important effect on pain 
perception and these relationships lie in the connectivity of brain regions controlling pain 
perception, attention or expectation, and emotional states.83 Patients with chronic pain may have 
alterations in brain regions involved in cognitive and emotional modulation of pain which may 
provide an explanation of why patients with chronic pain may have both psychological distress 
and physical manifestations of pain.84,85  Chronic pain may activate secondary mechanisms 
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within the central (central sensitization) and peripheral nervous system that can cause allodynia 
(sensitivity to non-noxious stimulus), hyperalgesia (increased sensitivity to pain), and 
hyperpathia (nocioceptive stimuli evokes exaggerated levels of pain) which often results in 
diminished function.86 Clinician must consider these factors when examining and treating 
patients with FM and MPS.  
FM and MPS may also be accompanied by other chronic conditions such as chronic 
headaches, temporomandibular disorder, irritable bowel syndrome, and interstitial 
cystitis/irritable bladder. Chronic pain conditions often cluster together in an individual. These 
conditions may fluctuate with one chronic condition becoming more dominant at a given point in 
time. 83,85 FM and MPS may also be clustered with other symptoms such as fatigue, poor sleep, 
poor cognition, and mood disturbances.83,87  
The examination of the patient with chronic pain can be challenging due to the 
physiological and psychological changes that occur with these conditions. This is compounded 
by the clustering with other chronic conditions. Thus, the physical examination of these 
individuals through palpation, which is often required for diagnosis, may be difficult due to the 
variability in responses and magnification of pain severity by the patient.72,88 Patients may 
present with allodynia, hyperalgesia, or hyperpathia, and also demonstrate an emotional fear 
response to testing due to the pain or past experience.  
2.6 Standard Manual Palpation: Challenges 
Several systematic reviews examining the efficacy of standard soft-tissue, motion, and 
pressure palpation for neck and back pain have found the overall reliability of palpation to be 
weak with no superior method established.19-21 Manual pressure palpation for pain seemed to 
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have the greatest reliability followed by motion palpation and soft-tissue palpation. Among all 
studies, intrarater reliability was better than interrater reliability.19-21 The common limitations 
reported among reviews were the methodological variability and lack of standardization among 
studies which has created a gap in our knowledge about the manual palpation examination.19-21 
Other studies on manual pressure palpation of nerves89, pelvic landmarks90, patellar position91, 
forearm muscles63, and upper extremity muscles92,93 have produced similar variable outcomes. 
These results have created an unclear translation from research to clinical practice and the 
development of a reference standard for technique, amount of applied pressure, and 
interpretation of findings.  
Clinicians often adopt their own methods of manual palpation with no objective way of 
measuring, documenting, and communicating their findings. If resources are available, clinicians 
may use instruments such as pressure algometry to quantify a patient’s pressure pain 
threshold.22,23 Also, clinicians may use patient related outcome measures (PROs) such as the 
numeric pain rating scale (NPRS) or visual analog scale (VAS) to measure and track a patient’s 
progress.31 These instruments and PROs are discussed in the following sections. To date, 
clinicians do not have a means of independently and objectively measuring their findings outside 
of these clinical tools. 
2.7 Patient Related Outcome Measures  
As mentioned above, Okifuji et al16 expanded the ACR palpation protocol by using the 
MTPS which is an NPRS. Clinicians often use PROs such as the NPRS and VAS to measure and 
track a patient’s progress.31 These outcome measures are commonly used in studies involving 
pressure pain threshold testing using manual palpation and algometry.31-33  
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Investigations have shown that the NPRS has good test-retest reliability (r=.94-.96).34,94-96 
Investigations have shown that the VAS has good test-retest reliability (r=.94).34 Other studies 
combining manual palpation pressure and the VAS for pain in subjects with FM have produced 
good results.96,97 A strong association (ICC=.86-.95) exists between the NPRS and the VAS when 
used with chronic pain disorders such as MPS and FM.34,94-96 The subjective nature of  PROs is 
an inherent weakness and is often influenced by the various dimensions of chronic pain.34 
Despite this limitation, the NPRS and VAS are common outcome measures used to document 
and communicate a patient’s pressure pain threshold. These outcome measures are further 
described in chapter 3.    
2.8 Instrumentation used in the Assessment of MPS and FM 
Algometry 
Along with manual palpation, pressure algometry is used in the assessment of individuals 
with MPS and FM.98 Pressure algometry is a mechanical form of pain assessment using a 
pressure gauge attached to a rubber tipped plunger.38 The instrument is pressed against a pre-
determined musculoskeletal region until a perceived maximum level of pain is produced.99 
Different types of algometry are available including hand-held spring loaded, digital, or 
computer based devices with a strain or pneumatic pressure gauge.25,28,29  Newer computer based 
algometers, such as the J-Tech Tracker Freedom® algometer (Midvale, UT) (Figure 2.3), offer a 
level of objectivity and pressure standardization that may be absent from other non-computerized 
algometers as well as novel to the existing research on PPT scales.99 The manufacturer reports an 
accuracy error of <± 0.5% (.05kg/cm2) for this technology. 99 The accompanying software 
calibrates the algometer before each test and includes specific examination protocols such as the 
ACR tender point criteria for diagnosing FM.15 The software visually guides the examiner, on 
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the monitor, as they apply pressure to the tender point site and then signals the examiner to stop 
when the pressure level is met. The J-Tech Tracker Freedom® algometer has been used in 
several investigations that examined lumbar spine mobilization100, manual therapy for shoulder 
impingement101, Acai berry consumption and pain102, and the relationship between neck pain and 
physical activity103.  
 
Figure 2.3 J-Tech Tracker Freedom® Algometer  
Several researchers have investigated the reliability of pressure algometry. Chesterton et 
al26 examined the interrater reliability among 5 newly trained raters in assessing PPT using a 
digital algometer on the first dorsal interosseous muscle in 13 healthy subjects. The authors 
found good reliability among all raters (ICC=.90). Nussbaum and Downes104 examined the 
reliability among 2 trained raters in assessing PPT using digital pressure algometry on the biceps 
brachii muscle over 3 consecutive days in 35 healthy subjects. The authors found good interrater 
reliability (ICC= .74-.89) among the raters.104  
Persson et al 92 also examined the test-retest reliability of PPT in shoulder muscles over 4 
sessions (Days 1,3,28,30) in 24 healthy female subjects (mean age 42 years). Two examiners 
used a digital algometer to measure the bilateral PPT over the trapezius and deltoid muscles. The 
authors found moderate to good interrater reliability among examiners for all sessions (ICC=.70-
.94). Moderate to good reliability was found between points for each muscle: trapezius: right 
(ICC=.59-.77), left (ICC=.67-.84), deltoid: right (ICC= .66-.83), left (ICC=.70-.90).   
 31 
 
Park et al35 assessed the PPT using digital algometry in the diagnosis of MPS in 222 
subjects (113 males, 108 females; mean age 43.2 years) using 5 trained raters. They evaluated 
the reliability, sensitivity, specificity, of applied pressure to six upper extremity muscles which 
included the: bilateral trapezius, infraspinatus, and extensor carpi radialis. One hundred fifty-six 
out of 222 subjects (72%) were diagnosed with MPS. The authors found good intrarater 
reliability among all muscles (Cronbach’s alpha= .94-.98). The specificity of the applied pressure 
for each muscle was as follows: trapezius (55%), infraspinatus (70%), and extensor carpi radialis 
(80%). The sensitivity was as follows: trapezius (42%), infraspinatus (30%), and extensor carpi 
radialis (5%).35 Other authors have found similar reliable outcomes in assessing PPT with 
algometry in the muscles of the temporomandibular joint,105-107 neck,108 shoulder,57 and 
abdominal wall in women.109,110  This research suggests that pressure algometry is a reliable 
measure of PPT among examiners over several sessions. 
Wolfe et al15 also used algometry in their 1990 investigation that led to the development 
of the ACR tender point criteria for the classification of FM. Please see above for more details on 
the performance of algometry in this investigation.  
Digital Pressure Sensor  
Standard manual palpation can be enhanced with the use of a digital pressure sensor to 
measure the pressure palpation force applied by the examiner. Bendtsen et al111,112 first 
introduced this technology back in 1994 and coined it the “palpometer.” The technology uses a 
thin pressure sensing film connected to data collection hardware. The preliminary studies in the 
1990’s reported this technology to be valid and reliable for measuring pressure pain 
thresholds.112,113 A more recent study by Fryer et al114 measured the reliability of the digital 
algometer to determine PPT of thoracic paraspinal tissue in 32 subjects. The subjects laid prone 
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while one examiner (blinded to the results) applied pressure at 3 predetermined thoracic 
paraspinal regions. The authors reported good intra-rater reliability (ICC=.95) for the three 
regions.114 Futarmal et al115 and Kothari et al116 both looked at test-retest variability among 
clinicians (N=12, N=16) between a digital pressure sensor and manual palpation at 
predetermined sites on the hand and fingers. Both studies calculated the coefficient of variation 
and found lower test-retest variability among raters using the digital pressure sensor versus 
manual palpation.115,116 Other studies have shown this technology to be valid and reliable for 
measuring PPT in craniofacial muscles105,117,118 and intraoral structures.119      
Tekscan® (South Boston, MA) has expanded this technology by creating a wireless 
version of the pressure sensor. The system uses a thin pressure sensing film connected to a 
wireless transmitter that sends concurrent data to a laptop computer (Figure 2.4). This is the 
same technology that Bendtsen et al111,112 and Fryer et al114 adapted for their investigations but 
with a wireless feature. Tekscan® reports an accuracy error of <±3% (.03kg/cm2) for this 
technology.120 The pressure sensor has been utilized in several research studies focusing on 
concussions,58 balance,121 knee joint biomechanics,30 dentistry,122 and gait.123 To date, this 
technology has not been used for measuring manual PPT in individuals diagnosed with MPS and 
FM.  
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Figure 2.4 Tekscan® Digital Pressure Sensor with WiFi Transmitter 
2.9 Summary of Literature 
The clinical presentations of MPS and FM are unique except for one common variable: 
the presence of TrPs.  Research from Alonso-Blanco et al41  and Ge et al42 suggests that 
individuals with FM also have concomitant TrPs at the predetermined tender point sites. 
Clinicians and researchers commonly diagnose tender points and TrPs using manual pressure 
palpation techniques that lack standardization and uniform reporting procedures.37  
Currently, there is no consensus on the assessment technique of manual pressure 
palpation despite what is taught in physical therapy education programs and what is defined in 
the Guide to Physical Therapy Practice.1,2,4 Chronic conditions such as MPS and FM depend on 
the manual pressure palpation examination for diagnosis since other medical tests (e.g. blood 
test) and imaging are inconclusive.5,35 Wolf et al15 and Okifuji et al16 were the first to use a 
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manual palpation protocol (ACR diagnostic criteria) that included a rating scale for manual 
pressure palpation for diagnosing patients with FM. These protocols have lacked further study 
since their original publication in the 1990’s. 
Due to the lack of consensus and standardization in the palpation examination for chronic 
pain conditions such as MPS and FM, there is a need for a valid and reliable pressure pain 
threshold scale (PPTS). The primary clinical finding for all the aforementioned diagnoses is the 
patient’s subjective report of pain or tenderness to palpation, which can be influenced by the 
amount of force applied and accuracy of palpation. The efficacy of a PPTS can be enhanced by 
the use of instruments such as a pressure sensor or algometer which can provide concurrent 
monitoring of rate and amount of pressure during the examination. The use of PROs such as the 
MTPS and VAS can also provide a good measure of the patient’s perceived level of pain. Thus, 
the combined use of the PPTS, digital pressure sensor, computerized algometer, NPRS and VAS 
pain scales, and the 1990 ACR diagnostic criteria may provide a more valid and reliable 
assessment than the existing protocols that were published in the 1990’s. 
2.91 Contribution of this Dissertation  
 
The development and utilization of a valid and reliable PPTS may have broad clinical 
application and provide a standardized way of assessing PPT as required for clinicians and 
researchers to communicate their findings. Moreover, a valid and reliably scale may also provide 
a clearer basis for identifying tissue reactivity as it can be better used in clinical studies for 
chronic pain conditions such as MPS and FM. For educators in physical therapy programs, a 
universally valid and reliable PPTS may enhance the teaching and interpretation of findings for 
manual pressure palpation.   
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Chapter 3 
 
3.0 Introduction  
 
This chapter outlines the methodology used to investigate the clinical questions for this 
dissertation project. This chapter will discuss the inclusion and exclusion criteria along with the 
recruitment methods used to recruit and assign participants to the designated groups. Methods of 
data collection with be outlined followed by the methods of data analysis. Last, the resources 
used for this investigation will be discussed with a final summary.   
3.1 Purpose and Clinical Questions 
The purpose of this dissertation was to validate a pressure pain threshold scale (PPTS) in 
patients diagnosed with myofascial pain syndrome (MPS) and fibromyalgia (FM). The validation 
of this new scale was determined by investigating the following clinical questions: 
Q1: What is the intrarater reliability of a 5-point PPTS in participants with MPS, FM, and 
healthy individuals (control group)?  
 Research Hypothesis (H1): There will be good intrarater reliability (ICC >.75) using 
the 5-point PPTS in participants with MPS, FM, and healthy individuals  
 
 Null Hypothesis (H01): There will not be good intrarater reliability (ICC >.75) using the 
5-point PPTS in participants with MPS, FM, and healthy individuals 
Q2: Does a 5-point PPTS possess concurrent validity when compared to a 10cm (100mm) 
visual analog pain scale at 18 predetermined tender points in participants with MPS and FM?  
 Research Hypothesis (H2): The 5-point PPTS will have a moderate to excellent 
relationship (rho ≥ .50) with the 10cm visual analog scale at 18 predetermined tender 
points in participants with MPS and FM  
 
 Null Hypothesis (H02): The 5-point PPTS will not have a moderate to excellent 
relationship (rho ≥ .50) with the 10cm visual analog scale at 18 predetermined tender 
points in participants with MPS and FM  
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Q3: Does a 5-point PPTS possess concurrent validity when compared to a manual tender point 
survey scale at 18 predetermined tender points in participants with MPS and FM?  
 Research Hypothesis (H3): The 5-point PPTS will have a moderate to excellent 
relationship (rho ≥ .50) with the manual tender point survey scale at 18 predetermined 
tender points in participants with MPS and FM 
  
 Null Hypothesis (H03): The 5-point PPTS will not have a moderate to excellent 
relationship (rho ≥ .50) with the manual tender point survey scale at 18 predetermined 
tender points in participants with MPS and FM  
Q4: Does manual palpation pressure up to 4 kg/cm2 measured by the Tekscan® Wireless ELF™ 
pressure sensor at 18 predetermined tender points produce a comparable response by the 
participant as algometry pressure up to 4 kg/cm2 using the 5-point PPTS in participants with 
MPS, FM, and in healthy individuals (control group)?  
 Research Hypothesis (H4): The Tekscan® Wireless ELF™ pressure sensor will have a 
moderate to excellent relationship (rho ≥ .50) with the algometer when using the 5-
point PPTS at 18 predetermined tender points in participants with MPS and FM.  
 Null Hypothesis (H04): The Tekscan® Wireless ELF™ pressure sensor will not have a 
moderate to excellent relationship (rho ≥ .50) with the algometer when using the 5-
point PPTS at 18 predetermined tender points in participants with MPS and FM. 
Q5: What is the cut-off value that differentiates participants with MPS and FM (combined) and 
healthy individuals (control group) using the 5-point PPTS? 
 Research Hypothesis (H5): A cut-off value of 2 will be the minimal difference on the 
5-point PPTS that differentiates participants with MPS and FM and healthy individuals.  
 Null Hypothesis (H05): A cut-off value of 2 will not be the minimal difference on the 5-
point PPTS that differentiates participants with MPS and FM and healthy individuals.  
 
3.2 Research Design and Approvals 
 
This dissertation was a three group observational study that investigated the reliability 
and validity of the PPTS. This study received Institutional Review Board approval by Nova 
Southeastern University and California State University Dominguez Hills. The approval letters 
can be found in Appendix A. To successfully complete this project adequate resources needed to 
be utilized. The study used 3 data collection sites: (1) Fibromyalgia of Huntington Beach in 
Fountain Valley, CA, (2) South Bay Orthopedic Specialists Medical Center in Torrance, CA, and 
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(3) California State University Dominguez Hills in Carson, CA. The approval letters can be 
found in Appendix B. Data collection was conducted by one examiner who was the principal 
investigator (PI) for this study.  
 
3.3 Participant Recruitment 
 
Participant recruitment (convenience sampling) was conducted using several methods. 
First, the PI attended different community group meetings for individuals with MPS and FM at 
Fibromyalgia of Huntington Beach. The PI invited interested individuals to participate in the 
study and also provided an approved flyer (Appendix C). Second, the staff from South Bay 
Orthopedics Medical Group provided the flyer to potentially eligible patients with contact 
information for the PI. Patients had the choice to contact the PI, if interested in participating in 
the study. Third, participants were recruited from the campus community at California State 
University Dominguez Hills. The approved flyer was displayed in several campus locations and 
the PI visited various campus group meetings and invited individuals.    
3.4 Description of Participants  
Eighty-four participants (N=84) who met the inclusion and exclusion criteria and 
consented to participate were enrolled in the study.  
Inclusion Criteria  
Participants included in this investigation were 18 to 65 years of age and met the criteria 
for 1 of the 3 groups. All participants were required to read, speak and write English as needed to 
complete forms and consent. Each group consisted of 28 participants. The following criteria for 
each group is outlined below: 
1. Control group: Individuals with no current or prior diagnosis consistent with MPS or 
FM. No integumentary injuries or abnormalities at the predetermined palpation sites. 
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2. MPS group: Individuals with a diagnosis of MPS that does not meet the American 
College of Rheumatology (ACR) diagnostic criteria for FM. No integumentary injuries or 
abnormalities at the predetermined palpation sites. 
3. FM group: Individuals who met the criteria for a diagnosis of FM based upon the ACR 
diagnostic criteria. No integumentary injuries or abnormalities at the predetermined 
palpation sites. 
 
Exclusion Criteria  
Prior to testing, participants filled out a screening questionnaire (Appendix D) with questions 
that represent the following exclusion criteria which were used to determine ineligibility for this 
study. The exclusion criteria were as follows:  
1. Current neurologic conditions (e.g. Multiple Sclerosis) 
2. Current metabolic conditions (e.g. Diabetic Neuropathy) 
3. Current systemic conditions (e.g. Rheumatoid Arthritis) 
4. Any skin or connective tissue problems (e.g. Marfan Syndrome) 
5. Current symptoms of numbness, tingling, burning, coldness, or pain in your back, hands, or 
feet. 
 
6. Any prior surgeries that may affect their ability to participate in this study.  
7. A pacemaker or electrical implant that may be affected by electronic equipment. 
8. Currently taking medications that may alter a subject’s sensation or affect their ability to 
participate in this study. 
9. Current shingles or post-herpetic neuralgia. 
10. Current open skin wounds on your neck, arms, back, or legs 
11. Current integumentary injury or abnormalities at palpation sites. 
12. Currently having other medical conditions or limited function that might affect participation. 
13. The ability to tolerate testing duration (45 minutes) and procedures. 
14. The ability to understand and complete all consent forms and questionnaires. 
 
3.5 Participant Enrollment and Consent  
Upon determining eligibility, participants were given an IRB approved consent form 
(Appendix E) to read and sign. The PI was available to answer any study related questions and 
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outline the testing procedures. Upon written consent, the PI began testing procedures or 
scheduled the participant for a future testing date. These forms are further discussed in section 
3.9 testing procedures. 
3.6 Patient Reported Outcome Measures  
During testing, all participants used two outcome measures to assess their perceived level 
of discomfort at each predetermined tender point. They are outlined below:  
Manual Tender Point Survey (MTPS): The MTPS is an 11-point numeric pain rating scale 
in which participant assigned a numerical value to quantify the perceived level of sensitivity they 
felt after the examiner tested each pre-determined point. The MTPS uses verbal descriptions as 
anchor points (0=no pain and 10=worst pain ever experienced) to help participants understand 
the scale. Numeric pain scales have been shown to be valid and reliable.34,95,97 Okifuji et al16 
utilized this scale in their investigation that diagnosed individuals with FM (Appendix F). 
Visual Analog Scale: The VAS is a pain assessment tool where the subject measures their 
pain level by marking a vertical line along a 10 cm (100 mm) horizontal line between two end 
points. The VAS has been shown to be valid and reliable (Appendix F).34,35,95  
3.7 Pressure Pain Threshold Scale  
The Pressure Pain Threshold Scale (PPTS) is a ranked scale newly designed for this 
investigation. The PPTS was used by the examiner during testing to measure the participant’s 
reactivity level. The PPTS is a 5-point ranked scale that includes corresponding criteria for each 
level (Table 3.1). Wolf et al15 developed a similar scale that used a scoring system but the 
clinimetric properties were never fully studied since their publication in the 1990’s.  
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Table 3.1. The Pressure Pain Threshold Scale 
3.8 Instrumentation 
Two clinical tools were used in this investigation. First, a digital pressure sensor was used 
to provide concurrent feedback of digital pressure during manual palpation. This technology has 
been validated and used before in prior studies.78,79 Second, a pressure algometer was also used 
to provide concurrent feedback and as a comparison for the digital pressure sensor. Algometry is 
a valid and reliable tool that is commonly used in research involving individuals with MPS and 
FM.35,92,104 A more comprehensive discussion of the clinimetric values of these instruments is 
provided in Chapter 2. A summary of these instruments is provided below: 
Digital Pressure Sensor: The Tekscan® (South Boston, MA) Wireless ELF™ 2 
computerized pressure system using the FlexiForce® sensor film was used during part I of the 
investigation. The EFL™ 2 system measured the pressure applied (up to 4km/cm2) by the 
examiner during the examination process. The sensor film was attached to the thumb which 
measured the pressure that was applied by the examiner (Figure 2.4) The sensor was connected 
to the accompanying software via Wi-Fi transmitter. The computer screen displayed a concurrent 
numeric reading of the amount of pressure being applied by the examiner in kilogram-force per 
square centimeter while the software recorded the session. This allowed the examiner to observe 
the amount of pressure being applied at each predetermined point. The software and hardware 
were calibrated before each testing session.  
Grade Interpretation Criteria 
0 No Pain No signs of pain or discomfort with pressure.  
I Mild Pain Tenderness reported without flinching to pressure.   
II Moderate Pain Wincing or flinching to pressure.   
III Severe Pain Signs of severe pain such as verbal gestures and 
withdrawing of body part to pressure.   
IV Noxious-Intolerable Pain Unbearable pain, patient does not allow palpation 
to the specific area of pain. 
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Pressure Algometry: The JTECH (Midvale, UT) Tracker Freedom® wireless algometer 
was used with the accompanying Tracker 5® software to measure the pressure (up to 4km/cm2) at 
each predetermined tender point in part II of the study. The algometer was connected to the 
computer via Bluetooth® wireless technology. The software visually guided the examiner, on the 
monitor, during testing. The computer screen displayed a concurrent numeric reading of the 
amount of pressure being applied by the examiner in kilogram-force per square centimeter while 
the software recorded the session. The subject also had a wireless remote button that they could 
press once their maximum level of discomfort was reached. This button stopped the test and the 
software immediately recorded the data. The software and hardware were calibrated before each 
testing session. 
3.9 Testing Procedures  
Prior to data collection, all participants filled out a questionnaire (Appendix D) to provide 
demographic information (age, body mass, gender, and arm dominance) and determine 
eligibility. If eligibility was determined, the participant was given an IRB approved consent form 
to read and sign (Appendix E). Once questions were answered to the prospective participant’s 
satisfaction, written consent was obtained. All participants underwent the same testing procedure 
and were blinded from the examiner’s scores and other participants enrolled in the study.  Testing 
was conducted between the hours of 8 A.M. and 2 P.M. and participants were instructed to 
refrain from taking any medication (e.g. pain medication or muscle relaxants) that would 
interfere with outcomes prior to testing. Participants were blinded from the investigator’s PPTS 
scores and from other participants enrolled in the study.  
Reliability Testing:  For the reliability portion of the study, the first 10 participants with 
the conditions of MPS or FM and the first 10 healthy participants (control group) underwent 1 
 42 
 
day of testing which lasted approximately 45 minutes. Participants were then offered to return for 
a 2nd day of testing (approximately 45 minutes) within one week of the first session. Participants 
underwent the same testing procedure each day. Recruitment continued until a total of 20 
participants were obtained for both the MPS and FM group and control group.  After the 
reliability testing was complete, all other recruited participants underwent 1 day of testing which 
lasted approximately 45 minutes.  
Testing Process: All participants underwent the same 2-part testing process that lasted 
approximately 45 minutes (part I: 20 minutes, part II: 20 minutes). Participants had the option to 
wear a gown with the back exposed and were instructed to wear their undergarments during 
testing. If not, clothing was move to expose the area of testing. All participants were placed in a 
seated position on a plinth or chair during testing. If the participant was unable to sit for the time 
period, they were placed in a prone or sidelying position. A mirror was placed in front of the 
participant to monitor their facial expressions during testing (Figure 3.1).  
Prior to testing, the PI demonstrated the procedure with each participant using 2 control 
points: left thumb (Part I), dorsum of the right forearm (Part II). This was done to familiarize the 
participant with the testing procedures, scoring of the PRO’s, and to answer any questions prior 
to testing. The control points were independent of the ACR 18 pre-determined points.16 Each part 
of the examination will be outlined below: 
Part I: Manual Palpation with Pressure Sensor: The PI applied a gradually increasing 
pressure to the American College of Rheumatology (ACR) 18 pre-determined points up to 
4kg/cm2 of pressure using the thumb and pressure sensor. The pressure was applied at a rate of 
1kg per second for a total of 4 seconds at each point, one time.15,16 The participant recorded their 
level of discomfort at each point using the MTPS and VAS pain scales once the PI reached 
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4kg/cm2 of pressure or once a maximum level of pressure was felt (Appendix F). Participants 
were able to stop testing at any time by verbally telling the examiner. The PI simultaneously 
recorded the participant’s response using the PPTS scale for each tender point (Appendix G). The 
pressure sensor was calibrated prior to testing each participant. 
Part II: Algometry: The PI applied a gradual increasing pressure to the 18 pre-determined 
points up to 4kg/cm2 of pressure using the computerized algometer. The pressure was applied at 
a rate of 1kg per second for a total of 4 seconds at each point, one time.15,16 The participant 
recorded their level of discomfort at each point using the MTPS and VAS pain scales once the 
examiner reached 4kg/cm2 of pressure or once a maximum level of pressure was felt (Appendix 
F). Participant’s also had the choice to press a wireless button, once a maximum level of pressure 
was reached, to initiate an audio chime to stop testing. This also stopped the device from 
recording pressure. Participants were able to stop testing at any time by verbally telling the 
examiner. The PI simultaneously recorded the participant’s response using the PPTS scale for 
each tender point (Appendix G). The algometer was calibrated prior to testing each participant. 
 
Figure 3.1 Testing lab at California State University Dominguez Hills 
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Tender points: The pre-determined tender points and control points were based upon the 
ACR diagnostic criteria for fibromyalgia15 and by the work of Okifuji et al.16 The test included 
18 predetermined tender points and 2 control points along the neck, back, arms, and legs. Below 
is a list of the specific points (note: bilateral testing for 18 points and 2 control* points for a total 
of 20 points). 
1) Posterior: (1) occiput (suboccipital muscle insertions), (2) trapezius (midpoint of the 
upper scapular border), (3) supraspinatus (above medial border of the scapular spine), (4) 
gluteal (upper outer quadrant of buttocks), (5) greater trochanter (posterior to trochanteric 
prominence) 
2) Anterior: (6) low cervical (anterior intertransverse space C5-C7), (7) second rib (2nd 
costocondral junction), (8) lateral epicondyle (2cm distal to epicondyle), (9) knee (medial 
fat pad proximal to joint line), (10) left thumbnail*, (11) dorsum R forearm (junction of 
proximal 2/3 and distal 1/3) *   
3.91 Sample Size and Power  
Prior to data collection, an a priori power analysis was conducted using the G*Power 
software124 for a moderate effect size (r=.30) as defined by Cohen.125 Based upon this test, power 
was set at 0.8, alpha level equal to .05 for a sample size of N=84 using a 2 tailed test. Each of the 
three groups had 28 participants for a total of 84 study participants.  
3.92 Data Analysis 
Statistical calculations were conducted with SPSS v.22 (IBM SPSS, Chicago, IL). The 
various statistics used to calculate the data related to the clinical questions are described below.  
The P-value was considered significant at the .05 level using a two-tailed test (α2 =.05) for all 
clinical questions outlined below.  
Participant Data: Descriptive data for age, body mass, height, and body mass index (BMI) 
was calculated for each group. Means standard error of mean (SEM), 95% confidence intervals 
(95% CI), and ranges of the ratio descriptive data from each group were calculated and presented 
in tabular format. Group differences were calculated using the ANOVA test for continuous level 
data and the Kruskall Wallis test for ordinal level data.   
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Question #1: What is the intrarater reliability of a 5-point PPTS in participants with MPS, 
FM, and healthy individuals (control group)? The intraclass correlation coefficient (ICC) model 
3, K statistic was used to calculate intrarater reliability. The criteria for evaluating the reliability 
coefficient was as follows: <.75 = poor to moderate, ≥.75 = good reliability.126 
Question #2: Does a 5-point PPTS possess concurrent validity when compared to a 10cm 
(100mm) visual analog pain scale at 18 predetermined tender points in participants with MPS 
and FM? The spearman rank correlation coefficient was used to calculate the data for this 
question (95% limits of agreement). The criteria for the evaluating the correlation coefficient was 
as follows: .00-.25 = little or no relationship, .25-.49 = fair relationship, .50-.75 = moderate to 
good relationship, and values greater than .75 = excellent relationship.126 
Question #3: Does a 5-point PPTS possess concurrent validity when compared to a manual 
tender point survey scale at 18 predetermined tender points in participants with MPS and 
FM?  The spearman rank correlation coefficient was used to calculate the data for this question 
(95% limits of agreement). The criteria for evaluating the correlation coefficient is outlined 
above in question #2. 
Question #4: Does manual palpation pressure up to 4kg/cm2 measured by the Tekscan® 
Wireless ELF™ pressure sensor at 18 predetermined tender points produce a comparable 
response by the participant as algometry pressure up to 4kg/cm2 using the 5-point PPTS in 
participants with MPS, FM, and in healthy individuals (control group)? The spearman rank 
correlation coefficient was used to calculate the data for this question (95% limits of agreement). 
The criteria for evaluating the correlation coefficient is outlined above in question #2. 
Question #5: What is the cut-off value that differentiates participants with MPS and FM 
(combined) and healthy individuals (control group) using the 5-point PPTS? The receiver 
operating characteristic (ROC) curve was used to calculate the data for this question. The ROC 
curve is an anchor based method of calculating the optimal cut-off value.127  The optimal cut-off 
value is represented by the maximum sensitivity and specificity situated highest on the upper left 
side of the ROC curve.128 The area under the curve (AUC) represents the probability of scores 
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accurately differentiating between patients. The AUC criteria ranges from 0.5 to 1. A score of 0.7 
to 0.8 is considered an acceptable discriminating range and 0.8 to 0.9 is considered an excellent 
discriminating range.129 The sensitivity, specificity, likelihood ratios, and predictive values were 
also calculated for this question based upon the previous work of Okifuji, et al.16 
3.93 Resources 
 
Internal grant funding from California State University Dominguez Hills was obtained 
for the amount of $4,000 which covered the costs for equipment, study related materials, and a 
$20 no-fee gift card given to each participant for completing the study. 
 
3.94 Summary  
 
This chapter details the methodology used to perform the investigation to validate a PPTS 
in participants with a diagnosis characterized by MPS and FM. A comprehensive research 
project such as this requires careful planning of appropriate testing protocols, data collection, and 
analysis. Internal validity was maximized through the selection of reliable instruments, strict 
adherence to a testing procedures, blinding the participants from the PI’s scores and other 
participants enrolled in the study. External validity was ensured through the use of a standard 
testing protocol, outcomes measures, and validated instrumentation that have been used in prior 
research in individuals with MPS and FM. The outcomes of this investigation can only be 
generalized to the population studied.  
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Chapter 4: Results 
 
4.0 Introduction  
 
This chapter will provide a summary of the results of this investigation on validating a 
pressure pain threshold scale (PPTS) in individuals with myofascial pain syndrome (MPS) and 
fibromyalgia (FM). Participant demographic data and outcomes for the five clinical questions 
related to this investigation will be summarized in this chapter. For each clinical question, the 
results of part I: manual palpation with pressure sensor and part II: algometry will be discussed.  
4.1 Participants  
 Eighty-four participants aged 18-65 (Mean 43.8) participated in the investigation. 
Statistical analysis revealed no significant differences (p>.21) between the MPS, FM, and control 
groups for age, height, body mass, and body mass index (BMI). The mean (continuous data), 
median (ordinal data), standard deviation (SD), range, and 95% confidence intervals (95% CI) 
for age, height, body mass, and BMI for each of the groups is listed in Table 4.1.  
Table 4.1 Participant Demographics  
Characteristics (n) Total (84) Control (28) MPS (28) 
  
FM (28) Comparison 
p-value 
Gender  M/F 18/66 9/19 7/21 2/26   
Age (years) Mean (SD) 
95% CI 
Range 
43.81 (14.59) 
41.01-47.27 
18-65 
41.32 (13.62)  
36.53-46.44 
22-65 
43.57 (16.50) 
37.53-51.98 
18-65 
46.44 (13.65) 
41.24-52.37 
22-65 
.42* 
Height 
(inches) 
Mean (SD) 
95% CI 
Range 
64.95 (4.01) 
64.13-66.18 
48-76 
65.25 (4.23) 
63.89-66.18 
59-76 
64.57 (4.80) 
62.69-66.26 
48-74 
65.03 (3.00) 
63.84-66.18 
61-74 
.82* 
Body Mass 
(lbs) 
Mean (SD) 
95% CI 
Range 
174.86 (38.94) 
166.72-183.37 
107-295 
166.78 (34.56) 
154.31-181.07 
107-235 
181.21 (42.57) 
166.60-197.64 
113-295 
176.57 (39.70) 
157.46-191.25 
113-280 
.37* 
Body Mass 
Index 
Median 
95% CI 
Range 
27.76  
27.90-30.86 
19-61 
25.55 
25.15-30.06 
20.9-45.9 
29.00 
28.41-34.33 
20.7-61.0 
28.75 
26.29-31.68 
19.0-43.9 
.21** 
FM: Fibromyalgia; MPS: Myofascial Pain Syndrome; n: number of subjects  
M: male; F: female; SD: standard deviation; Group Comparison p-values: * ANOVA test; **Kruskall Wallis test  
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4.2 Aim #1  
 
What is the intrarater reliability of a 5-point PPTS in participants with MPS, FM, and healthy 
individuals (control group)? 
 
For this investigation, a reliability analysis was undertaken using the first 10 participants 
from the combined MPS and FM group and 10 participants from the control group for a total of 
20 participants. The results of the selected measures for part I and II of testing are discussed 
below: 
Part I: Manual Palpation with Pressure Sensor  
The digital pressure sensor was used with the thumb to measure the amount of applied 
pressure at each predetermined tender point while the participant’s response was graded using 
the PPTS. The intrarater reliability was good for the combined MPS and FM group (ICC model 
3, k =.92) and the control group (ICC model 3, k =.91) (Table 4.2).  
 
Part II: Algometry  
The algometer was used to measure the amount of applied pressure at each 
predetermined tender point while the participant’s response was graded using the PPTS. The 
intrarater reliability was good for the combined MPS and FM group (ICC model 3, k =.88) and 
the control group (ICC model 3, k=.90) (Table 4.2).  
 
Table 4.2 Intrarater Reliability Values for Part I and Part II 
  Group (n) ICC (3, k) 95% CI 
Part I: Manual palpation 
with pressure sensor 
Control (10) .91 .88-.93 
MPS/FM (10) .92 .89-.94 
Part II: Algometry Control (10) .90 .87-.92 
MPS/FM (10) .88 .84-.91 
FM: Fibromyalgia; MPS: Myofascial Pain Syndrome; n: number of subjects  
ICC Model 3, k: intraclass correlation coefficient; CI: confidence interval  
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4.3 Aim #2 
Does a 5-point PPTS possess concurrent validity when compared to a 10cm (100mm) 
visual analog pain scale at 18 predetermined tender points in participants with MPS and FM? 
 
Part I: Manual Palpation with Digital Pressure Sensor 
 A good to excellent relationship (rho ≥ .76, p<.001) was found among all 18 points 
between the PPTS and the visual analog scale (VAS) for all three groups. The results for each 
group are displayed in Appendix H.   
Part II: Algometry  
A moderate to excellent relationship (rho ≥ .61, p<.001) was found among all 18 points 
between the PPTS and the VAS for all three groups. The results for each group are displayed in 
Appendix H.  
4.4 Aim #3  
Does a 5-point PPTS possess concurrent validity when compared to a manual tender 
point survey (MTPS) scale at 18 predetermined tender points in participants with MPS and FM?   
 
Part I: Manual Palpation with Pressure Sensor  
A moderate to excellent relationship (rho ≥ .71, p<.001) was found among all 18 points 
between the PPTS and the manual tender point rating survey (MTPS) for the MPS and control 
groups. A little to moderate relationship was found among all 18 points for the FM group (rho= 
.01-.50, p=.97-.007). The results for each group are displayed in Appendix I.   
Part II: Algometry  
A moderate to excellent relationship (rho ≥ .68, p<.001) was found among all 18 points 
between the PPTS and the MTPS for all three groups. The results for each group are displayed in 
Appendix I.   
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4.5 Aim #4 
Does manual palpation pressure up to 4kg/cm2 measured by the Tekscan® Wireless 
ELF™ pressure sensor at 18 predetermined tender points produce a comparable response by the 
participant as algometry pressure up to 4kg/cm2 using the 5-point PPTS in participants with 
MPS, FM, and in healthy individuals (control group)?  
 
A fair to excellent relationship (rho ≥ .41, p=.03) was found among all 18 points between 
the digital pressure sensor and algometer using the PPTS for all three groups. The results for 
each group are displayed in Appendix J.   
4.6 Aim #5 
What is the cut-off value that differentiates participants with MPS and FM (combined) and 
healthy individuals (control group) using the 5-point PPTS? 
 
For this analysis, a receiver operating characteristic (ROC) curve was used to determine 
the minimal cut-off value that differentiated the MPS and FM group and control group. 
Participant data was dichotomized into two categories: (1) MPS and FM group and (2) control 
group. Also, the combined MPS and FM group was compared to the control group to determine 
sensitivity, specificity, likelihood ratios, and predictive values. The calculations of the ranked 
scores were adapted from the methods described by Okifuji et al16.   
Phase I: Manual Palpation with Pressure Sensor 
For phase I: manual palpation, an optimal cut-off value of 2 (AUC .841, 95% CI .82-.86) 
differentiated participants in the MPS and FM group from the control group (Table 4.3). 
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Table 4.3 ROC Curve (Part I: Manual Palpation) 
 
When calculating the numerical threshold of manual palpation, a cut-off value of 2 
(sensitivity=.22, specificity=.97) was determined to be the optimal threshold score to 
differentiate the MPS and FM group from the control group (Table 4.4). Thus, a ranked score of 
2 or greater would be confirmative for individuals with MPS and FM. 
Table 4.4 Numeric Threshold for PPTS (Part I: Manual Palpation) 
Score Sensitivity 
(95% CI) 
Specificity  
(95% CI) 
+ LR 
(95% CI) 
-LR 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
0 .12 (.11-.15) .33 (.29-.37) .19 (.16-.23) 2.69 (2.54-2.71) .28 (.24-.32) .16 (.14-.18) 
1 .35 (.32-38) .71 (.66-.75) 1.19 (1.01-1.40) .92 (.88-.96) .70 (.66-.74) .35 (.32-.38) 
2 .22 (.19-.25) .97 (.95-.98) 8.46 (4.89-14.65) .80 (.78-.83) .94 (.90-.97) .38 (.36-.41) 
3 .29 (.26-.32) .99 (.97-.99) 24.42 (10.96-54.40) .71 (.68-.74) .98(.95-.99) .41 (.38-.44)  
4 .01(.004-.017) 1.0 (.99-1.00) 10.0 (.99-1.00) .99 (.98-1.00) 1.0 (.63-1.00) .33 (.31-.36) 
FM: Fibromyalgia; MPS: Myofascial Pain Syndrome; n: number of subjects  
LR: likelihood ratios; PPV: positive predictive values; NPV: negative predictive values; CI: confidence interval 
 
Part II: Algometry  
For phase II algometry, an optimal cut-off value of 2 (AUC .841, 95% CI .82-.86) 
differentiated participants in the MPS and FM group from the control group (Table 4.5).  
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Table 4.5 ROC Curve (Part II: Algometry) 
 
When calculating the numerical threshold of algometry, a cut-off value of 2 (sensitivity= 
.20, specificity=.96) was determined to be the optimal threshold score to differentiate the MPS 
and FM group from the control group (Table 4.6). Thus, a ranked score of 2 or greater would be 
a clinically meaningful cut-point for individuals with MPS and FM. 
 
Table 4.6 Numeric Threshold for PPTS (Part II: Algometry)  
Score  Sensitivity 
(95% CI) 
Specificity  
(95% CI) 
+ LR 
(95% CI) 
-LR 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
0 .10(.08-.12) .41(.37-.46) .16(.13-.20) 2.19(2.13-2.25) .25(.20-.29) .18(.16-.21) 
1 .31(.28-.34) .67(.61-.70) .91(.78-1.06) 1.04(1.0-1.09) .65(.60-.69) .32(.29-.35) 
2 .20(.18-.23) .96(.94-.97) 5.17(3.31-8.09) 0.83(.80-.85) .91(.86-.94) .38(.35-.40) 
3 .37(.34-.40) .97(.95-.98) 12.4(7.48-20.54) .65(.62-.68) .96(.93-.98) .43(.40-.46)  
4 .02(.01-.03) 1.0(.99-1.00) 10 (9.6-11.30) .98 (.97-.99) 1.0 (.77-1.00) .34(.31-.36) 
FM: Fibromyalgia; MPS: Myofascial Pain Syndrome; n: number of subjects  
LR: likelihood ratios; PPV: positive predictive values; NPV: negative predictive values; CI: confidence interval 
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4.7 Summary of Findings  
The results of this investigation revealed good intrarater reliability (ICC ≥ .88) when using 
the PPTS with both the algometer and pressure sensor for all three groups.  The PPTS was found 
to have a moderate to excellent relationship (rho ≥ .61) among all 18 points with the VAS for all 
three groups using both devices. The PPTS had a moderate to excellent relationship (rho ≥ .68) 
among all 18 points with the MTPS for all three groups using the algometer. The PPTS also had 
a moderate to excellent relationship (rho ≥ .71) among all 18 points with the MTPS for the MPS 
and control group using the pressure sensor. The PPTS had a little to moderate relationship (rho 
=.01-.50) among all 18 points with the MTPS for the FM group using the pressure sensor. When 
comparing the performance of the pressure sensor to the algometer, there was a fair to excellent 
relationship (rho ≥ .41) among all 18 point using the PPTS for all groups. The cut-off value of 2 
on the PPTS differentiated participants with MPS and FM from healthy participants (controls).   
 
4.8 Conclusion 
This chapter provided a summary of the results from the statistical calculations for the 
five research questions developed for this investigation. Appendices H to J provide a more 
detailed summary of the calculations for research questions 2 to 4. The next section provides a 
discussion and interpretation of the results of this investigation.  
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Chapter 5: Discussion 
5.0 Introduction  
This chapter provides a summary and interpretation of the results of this investigation. 
The first section will provide a discussion of the finding for each research question, the related 
research, and the impact on clinical practice. The second section will discuss study limitation, 
delimitations, implications for physical therapy practice, and recommendations for future 
research.  
5.1 Discussion: Aim #1 Reliability 
Several systematic reviews have examined the efficacy of manual palpation of soft-tissue, 
motion, and pain. The consensus is that the reliability of palpation is weak with no superior 
method established.19-21  When considering the available evidence, manual pressure palpation for 
pain has the greatest intrarater reliability followed by motion and soft-tissue palpation.19-21 The 
existing examination protocols for myofascial pain syndrome (MPS) and fibromyalgia (FM) 
require manual pressure palpation and have similar challenges due to the poor methodology of 
supporting literature.15,64 These issues create a problem for clinical practice since clinicians do 
not have a valid and reliable method of assessing these individuals.  
The results of this study rejected the null hypothesis and supported the research 
hypothesis of good intrarater reliability among all three groups (ICC ≥ .88) using the PPTS. For 
the clinician, the PPTS may provide a consistent means of grading and communicating findings 
from the manual pressure palpation examination and can be used as a repeated measure 
throughout the treatment process. These findings build upon the previous research regarding the 
intrarater reliability of manual pressure palpation for pain.19  Thus, a clinician can reliably 
measure pressure pain thresholds in MPS and FM patients using the PPTS. Such a consistent 
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method is necessary since the symptoms of individuals with chronic pain can fluctuate and 
change daily.83,85 Future studies are needed to measure the interrater reliability of the PPTS in 
these individuals.  
5.2 Discussion: Aim #2 and Aim #3 Concurrent Validity 
 Currently, there is no reference standard scale to compare to the PPTS. For this 
investigation, the concurrent validity of the PPTS was measured against the visual analog scale 
(VAS) and a numeric pain rating scale (NPRS) called the manual tender point rating survey 
(MTPS). Both, the VAS and NPRS are reliable scales (r ≥ .94) that have a strong association 
(ICC=.86-.95) when used with chronic pain disorders such as MPS and FM.34,94-96 The results of 
the analyses are discussed below.   
For Aim #2, the results of the study rejected the null hypothesis and supported the 
research hypothesis of a moderate to excellent relationship between the PPTS and VAS for all 
three groups. Prior research combining manual pressure palpation and the VAS to assess pain in 
subjects with FM have produced good results.96,97 For Aim #3, the results of the study rejected 
the null hypothesis and supported the research hypothesis of a moderate to excellent relationship 
between the PPTS and MTPS for the MPS and control group. However, there was a little to 
moderate relationship between the PPTS and MTPS for the FM group which resulted in a failure 
to reject the null hypothesis for this group. The variability in the FM group may be due to the 
sample population used for this investigation. All FM participants (n=28) reported having the 
condition for 2 years or more. Prior research suggests an association between reported pain 
severity and the duration of FM since diagnosis. Patients who have suffered from FM for more 
than 2 years report higher scores on the NPRS.88,130 Also, the variability in the participants’ pain 
level may have influenced their scores. Research suggests that individuals with FM and MPS 
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have variable levels of pain which can fluctuate each day.42,131 This variability in pain may be 
due to a combination of biological, psychological, and social factors that interact to influence 
pain.83  
Clinically, it appears that the VAS may have better utility than the MTPS for examining 
individuals with MPS and FM. The MTPS may have some utility for the examination of MPS 
but needs further study. For research, the VAS may be superior than the NPRS. The VAS has 
ratio measurement properties that allow for parametric calculations versus an ordinal scale 
(NPRS) which requires a non-parametric statistic.132,133 
5.3 Discussion: Aim #4 Clinical Tools  
Two clinical tools were used for this investigation: an algometer and digital pressure 
sensor.  Algometry is a valid and reliable tool that is commonly used in research involving 
individuals with MPS and FM.35,92,104  The digital pressure sensor is an emerging technology 
used in prior research for soft-tissue palpation but never for chronic pain.111,112,114 The algometer 
was considered the comparison “gold standard” for this investigation.   
When comparing the performance of the two instruments there was fair to excellent 
relationship for all groups which resulted in rejection of the research hypothesis and acceptance 
of the null hypothesis. The results suggest that the algometer may have the best overall 
performance and should not be interchangeable with the digital pressure sensor. When 
considering the utility of both devices, the algometer may be preferable for research and clinical 
practice. The digital pressure sensor may serve best in physical therapy education. The digital 
pressure sensor may provide a means for faculty and students to concurrently monitor the applied 
pressure during the manual pressure palpation examination. The clinical tools used in this study 
may enhance the manual pressure palpation examination process but may not be available in all 
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clinical settings due to cost. Lastly, although algometry is perhaps superior, palpation with a 
digital pressure sensor more closely resembles clinical practice and still maintains a ranking 
needed for change. 
5.4 Discussion: Aim #5 Cut-off Value 
The ordinal ranked format of the PPTS provides the clinician with a means of measuring, 
documenting, and reporting examination findings. The clinimetric properties of the previously 
used scales were never fully studied and eventually were modified or omitted by other 
researchers.15,48,73,75 The findings from this study supported the research hypothesis that a cut-off 
value of 2 was the optimal threshold score that differentiated patients with MPS and FM from 
controls. Thus, a clinician may be able to discriminate between individuals based upon PPTS 
scoring. The original ACR criteria (at least 11/18 tender points) has been shown to be sensitive in 
diagnosing FM but unable to discriminate between individuals with FM and others chronic 
conditions or healthy subjects.15,51,71,73 For example, in 10-20% of the general population 
(healthy individuals) the ACR tender point count has been shown to be 10/18 in females and 6/18 
in males.71,134  
Research has also shown that a decrease in the number of tender point sites correlates 
poorly with patient improvement.135,136 Individuals with chronic pain also report higher pain 
levels than matched controls.73,88 This may be because tender point counts are believed to be a 
general measure of distress that’s influenced by cognitive and emotional aspects of pain 
perception.137-139  It has been recommended that the assessment of pain severity at tender point 
sites may be a better measure of tenderness than the change in tender point count.137 Thus, 
combining the ACR tender point criteria (at least 11/18) with the PPTS cut-off value of 2 may 
provide a more accurate method of differentiating between these individuals. The results from 
 58 
 
this study provide preliminary evidence for this hypothesis, 79 % (22/ 28) of FM participants 
presented with a PPTS score of ≥ 2 at 11 or more tender points versus 40% (11/28) of MPS 
participants, and 0% (0/28) of control participants. The ability of the PPTS to discriminate 
between FM and MPS patients still needs to be explored. This is pertinent for clinical practice 
since up to 50% of patients diagnosed with MPS have FM.52 The tender points in the upper body 
(cervical spine) tended to have higher reported scores that lower body tender points among all 
three groups. These findings are consistent with prior research demonstrating higher scores in the 
upper body tender points.48,134,140 
5.5 Implications for Physical Therapy Practice   
For this investigation, The PPTS was compared to the VAS and MTPS using the ACR 
tender point criteria.16,34,42 Two instruments were also used in this investigation: an algometer 
and digital pressure sensor. The ACR protocol included pressure palpation of 18 pre-determined 
tender point sites. A pressure of up to 4kg/cm2 at a rate of 1kg per second was applied to each 
tender point. The use of the instruments allowed the investigator to concurrently monitor and 
control the rate of pressure at each point while measuring the patient’s sensitivity with the PPTS. 
Such methods were never done in prior research.15,64 Pressure palpation can vary among tender 
points due to the type of tissues palpated, tissue density, and the patient’s level and response to 
pain.48 It appeared that the range of pressure (up to 4kg/cm2) was deep enough to accurately 
assess tender point sensitivity among all 18 tender points for all groups.15  
The results of this research suggest the combination of the PPTS, ACR criteria, patient 
related outcome measures, and clinical tools may enhance the examination process for these 
individuals. For MPS, the combination of the PPTS, VAS, MTPS, algometer or pressure sensor 
may yield the best results. For FM, the combination of the PPTS, VAS, MTPS, and algometer 
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may provide the best outcomes. This preliminary research suggests that the PPTS is a valid and 
reliable scale for MPS and FM. The PPTS may have efficacy for other chronic pain and 
orthopedic conditions. Future studies are needed to determine the full utility of the scale. 
Suggestions for future research are provided in the subsequent section.     
5.6 Limitations  
When considering the methodology and the results of this investigation, some limitations 
warrant discussion.  A potential limitation of this investigation was age. The age (years) of 
participants ranged from 18-65 (Mean 43.8). The results cannot be generalized outside of this 
age range. Despite this limitation, the study participants did represent the common age range for 
individuals diagnosed with MPS and FM as well as the average age of patients receiving care in 
outpatient physical therapy clinics.3,7-10,141 Another potential limitation is the clinical course of 
individuals with chronic pain disorders such as MPS and FM. Often times, these individuals may 
feel different levels of musculoskeletal pain or symptoms on different days. Variations in a 
patient’s perceived pain is a confounding variable in this population and must be considered 
when interpreting the results of the research.13,113 Other limitations include the fact that all of the 
assessments used technology that may not be available in all clinical settings. The outcomes of 
the PPTS may be different if used without a digital pressure sensor or algometer. 
5.7 Delimitations  
There are several delimitations that warrant discussion for this investigation. First, MPS 
and FM were the only diagnoses studied which limits the generalizability of the investigation to 
these conditions and not to all the known chronic pain conditions. MPS and FM both require a 
manual pressure palpation examination as part of the diagnosis and are some of the most studied 
conditions among chronic pain pathologies.37,51,71,142 Second, the population studied contained 
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individuals with preexisting diagnoses of MPS and FM. This investigation did not attempt to 
determine the diagnostic accuracy of the PPTS. Future studies measuring the diagnostic value of 
the PPTS are warranted. Third, standard manual palpation was not measured in this 
investigation. The pressure sensor and algometer were used to help validate the PPTS. This 
technology allowed the examiner to concurrently measure the rate and amount of pressure that 
was applied during testing. Prior studies using standard manual palpation in this population have 
yielded variable results.37,66,70,70 Fourth, intrarater reliability was measured for this investigation. 
This limits the reliability of the PPTS to one examiner. Clinician’s will need to consider this 
when using the PPTS in clinical practice. Future studies are needed to establish reliablity among 
multiple clinicians.  
5.8 Recommendations for Future Research  
The results of this investigation provide evidence for the efficacy of the PPTS but are 
preliminary. Further research is necessary to validate the full utility of the PPTS. This section 
proposes recommendations for future research using the PPTS for clinical practice and 
education. For clinical practice, future investigations should focus on five key areas to further 
explore the utility of the PPTS. First, interrater reliability of the PPTS must be determined in 
order to establish its reliability among multiple clinicians. This investigation only measured 
intrarater reliability due to limited resources. Second, the diagnostic utility of the PPTS has yet to 
be determined. This investigation used participants with preexisting conditions. Future 
investigations are needed to measure the diagnostic properties of the PPTS in undiagnosed 
individuals suspected of having MPS and FM. Third, the efficacy of the PPTS for other chronic 
pain disorders (e.g. chronic fatigue syndrome) still needs to be investigated. Often, these 
conditions present with similar types of musculoskeletal pain.143 Fourth, the PPTS may provide a 
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good assessment of pressure pain thresholds for general orthopedic conditions such as 
tendinopathy. Future studies are needed to confirm this hypothesis. Fifth, the efficacy of PPTS 
using standard manual palpation needs to be investigated. This study utilized technology that 
may not be available in all clinical settings. Future research should explore the validity of the 
PPTS using standard palpation in comparison with this technology.  
The PPTS may be also be an effective teaching tool for physical therapy educators. The 
PPTS may provide a means for educators to measure, compare, and report a student’s 
performance during the graded manual pressure palpation examination. Future studies should 
focus on three main areas of education. First, entry-level Doctor of Physical Therapy (DPT) 
programs may be able to use the PPTS in their orthopedic curriculums. Future studies should 
explore the efficacy of the PPTS to measure the performance of graded manual pressure 
palpation among 2nd and 3rd year DPT students. Second, postgraduate orthopedic physical 
therapy residency programs may be able to use the PPTS in their curriculums. Future studies 
should explore the efficacy of the PPTS as a teaching tool and repeated measure within the 
residency curriculum. Third, the PPTS may be useful as a standard communication tool for 
palpation among allied health professionals. Future studies should measure the efficacy of the 
PPTS in helping educators teach, measure, and compare graded manual pressure palpation 
among various allied health professionals in order to develop interdisciplinary standards.  
5.9 Conclusion  
The results from this study provide preliminary evidence validating the PPTS scale in 
individuals with MPS and FM. The PPTS may have utility for both clinicians and educators. The 
PPTS may provide an object means to measure, document, and communicate pressure pain 
thresholds. The efficacy of the PPTS can be enhanced by the use of instruments such as a digital 
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pressure sensor or algometer which can provide concurrent monitoring of the rate and amount of 
pressure during the examination. Future research is needed to further study the clinimetric 
properties of the PPTS. In particular, future studies are needed to determine interrater reliability, 
diagnostic accuracy, and efficacy of the PPTS as a teaching tool for physical therapy and 
interdisciplinary allied health education.   
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Aim #2: Does a 5-point PPTS possess concurrent validity when compared to a 
10cm (100mm) visual analog pain scale at 18 predetermined tender points in 
participants with MPS and FM?  
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Part I: Manual Palpation with Pressure Sensor 
 
Control Group Comparison 
 
 
 
 
 
 Descriptive Data: 18 points (Group n=28)  
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Control Group Manual Palpation: PPTS compared to VAS 
Points Spearman rho 95% CI Correlation p-value 
1 .89 .79 to .94 <.001 
2 .93 .82 to .97 <.001 
3 .97 .92 to .99 <.001 
4 .80 .57 to .98 <.001 
5 .97 .93 to 1.0 <.001 
6 .81 .53 to .98 <.001 
7 .99 .98 to 1.0 <.001 
8 .99 .99 to 1.0 <.001 
9 .93 .83 to .99 <.001 
10 .86 .68 to .95 <.001 
11 .83 .64 to .98 <.001 
12 .84 .60 to .98 <.001 
13 .79 .42 to .99 <.001 
14 .78 .42 to 1.0 <.001 
15 .76 .40 to 1.0 <.001 
16 .92 .74 to 1.0 <.001 
17 .93 .71 to 1.0 <.001 
18 1.0 .98 to 1.0 <.001 
CI: Confidence Interval 
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FM Group Comparison 
 
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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FM Group Manual Palpation: PPTS compared to VAS  
Points Spearman rho 95% CI Correlation p-value 
1 .93 .88 to .95 <.001 
2 .88 .71 to .95 <.001 
3 .92 .73 to .96 <.001 
4 .90 .77 to .96 <.001 
5 .91 .76 to .97 <.001 
6 .93 .77 to .97 <.001 
7 .93 .87 to .96 <.001 
8 .91 .79 to .94 <.001 
9 .82 .64 to .93 <.001 
10 .79 .65 to .92 <.001 
11 .77 .56 to .89 <.001 
12 .83 .66 to .95 <.001 
13 .94 .89 to .97 <.001 
14 .89 .76 to .95 <.001 
15 .88 .80 to .93 <.001 
16 .91 .75 to .96 <.001 
17 .89 .84 to .94 <.001 
18 .94 .91 to .97 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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MPS Group Comparison 
 
 
   
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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MPS Group Manual Palpation: PPTS compared to VAS  
Points Spearman rho 95% CI Correlation p-value 
1 .93 .86 to .94 <.001 
2 .91 .81 to .94 <.001 
3 .96 .85 to .99 <.001 
4 .96 .88 to .98 <.001 
5 .94 .81 to .99 <.001 
6 .86 .62 to .93 <.001 
7 .96 .91 to .99 <.001 
8 .94 .84 to .98 <.001 
9 .91 .83 to .93 <.001 
10 .93 .87 to .94 <.001 
11 .91 .72 to .96 <.001 
12 .90 .76 to .96 <.001 
13 .97 .92 to .99 <.001 
14 .93 .76 to .98 <.001 
15 .93 .84 to .98 <.001 
16 .94 .86 to .96 <.001 
17 .96 .88 to .99 <.001 
18 .95 .82 to .99 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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Part II: Algometry 
 
Control Group Comparison 
 
 
  
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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Control Group Algometry: PPTS compared to VAS  
Points Spearman rho 95% CI Correlation p-value 
1 .90 .76 to .97 <.001 
2 .92 .81 to .97 <.001 
3 .97 .91 to 1.0 <.001 
4 .87 .61 to .99 <.001 
5 .99 .96 to 1.0 <.001 
6 .99 .95 to 1.0 <.001 
7 .99 .97 to 1.0 <.001 
8 .99 .98 to 1.0 <.001 
9 .90 .76 to .96 <.001 
10 .85 .67 to .97 <.001 
11 .96 .88 to .99 <.001 
12 .96 .88 to .99 <.001 
13 .97 .90 to .99 <.001 
14 .97 .93 to 1.0 <.001 
15 .91 .54 to 1.0 <.001 
16 .99 .97 to 1.0 <.001 
17 .98 .94 to 1.0 <.001 
18 .99 .95 to 1.0 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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FM Group Comparison 
 
 
 
  
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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FM Group Algometry: PPTS compared to VAS 
Points Spearman rho 95% CI Correlation p-value 
1 .77 .49 to .91 <.001 
2 .82 .60 to .94 <.001 
3 .79 .49 to .94 <.001 
4 .85 .62 to .94 <.001 
5 .82 .64 to .94 <.001 
6 .84 .51 to .94 <.001 
7 .84 .65 to .95 <.001 
8 .91 .71 to .97 <.001 
9 .61 .22 to .86 <.001 
10 .69 .43 to .88 <.001 
11 .82 .61 to .91 <.001 
12 .73 .28 to .90 <.001 
13 .88 .77 to .94 <.001 
14 .83 .59 to .90 <.001 
15 .88 .79 to .92 <.001 
16 .86 .69 to .92 <.001 
17 .70 .29 to .95 <.001 
18 .78 .24 to .96 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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MPS Group Comparison 
 
 
 
  
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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MPS Group Algometry: PPTS compared to VAS  
Points Spearman rho 95% CI Correlation p-value 
1 .90 .80 to .94 <.001 
2 .91 .83 to .94 <.001 
3 .97 .92 to .99 <.001 
4 .96 .91 to .97 <.001 
5 .94 .81 to .96 <.001 
6 .93 .84 to .96 <.001 
7 .97 .92 to .99 <.001 
8 .88 .70 to .98 <.001 
9 .93 .85 to .95 <.001 
10 .93 .87 to .95 <.001 
11 .92 .83 to .95 <.001 
12 .95 .91 to .97 <.001 
13 .93 .80 to .96 <.001 
14 .93 .85 to .96 <.001 
15 .94 .84 to .99 <.001 
16 .96 .90 to .99 <.001 
17 .94 .85 to .98 <.001 
18 .96 .83 to .99 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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Appendix I 
 
 
 
 
 
 
Aim #3: Does a 5-point PPTS possess concurrent validity when compared to a 
Manual Tender Point Survey Scale at 18 predetermined tender points in 
participants with MPS and FM? 
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Part I: Manual Palpation with Pressure Sensor 
 
Control Group Comparison 
 
 
  
 
 
 
Descriptive Data: 18 points (Group n=28) 
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Control Group Manual Palpation: PPTS compared to MTPS  
Points Spearman rho 95% CI Correlation p-value 
1 .89 .68 to 1.0 <.001 
2 .94 .80 to .99 <.001 
3 .98 .94 to .99 <.001 
4 .81 .58 to .99 <.001 
5 .97 .93 to .99 <.001 
6 .77 .53 to .99 <.001 
7 1.0 .99 to 1.0  <.001 
8 1.0 .99 to 1.0  <.001 
9 .94  .84 to .99 <.001 
10 .87 .76 to .96 <.001 
11 .87 .66 to .97 <.001 
12 .90 .77 to 1.0 <.001 
13 .79 .52 to 1.0 <.001 
14 .79 .43 to 1.0 <.001 
15 .71 .38 to 1.0 <.001 
16 .92 .65 to 1.0 <.001 
17 .92 .76 to .1.0 <.001 
18 1.0 1.0 to 1.0 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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FM Group Comparison 
 
 
 
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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FM Group Manual Palpation: PPTS compared to MTPS  
Points Spearman rho 95% CI Correlation p-value 
1 .24 -.38 to .55 .23 
2 .25 -.99 to .61 .20 
3 .26 -.61 to .59 .17 
4 .30 -.02 to .64 .13 
5 .31 -.15 to .64 .11 
6 .38 -.02 to .71 .05* 
7 .01 -.43 to .42 .97 
8 .32 -.14 to .73 .09 
9 .41 -.04 to .79 .03* 
10 .41 .03 to .72 .03* 
11 .30 -.14 to .67 .12 
12 .16 -.34 to .54 .42 
13 .14 -.34 to .54 .49 
14 .01 -.42 to .42 .97 
15 .30 -.24 to .66 .12 
16 .17 -.19 to .59 .39 
17 .25 -.29 to .61 .21 
18 .50 .11 to .78 .007* 
CI: Confidence Interval; *statistically significant p<.05 
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MPS Group Comparison 
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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MPS Group Manual Palpation: PPTS compared to MTPS  
Points Spearman rho 95% CI Correlation p-value 
1 .95 .90 to .96 <.001 
2 .93 .86 to .96 <.001 
3 .97 .91 to .99 <.001 
4 .97 .91 to .99 <.001 
5 .96 .90 to 1.0 <.001 
6 .87 .77 to .94 <.001 
7 .97 .92 to .99 <.001 
8 .95 .85 to .99 <.001 
9 .92 .83 to .95 <.001 
10 .94 .89 to .97 <.001 
11 .91 .81 to .96 <.001 
12 .94 .85 to .97 <.001 
13 .98 .94 to .99 <.001 
14 .94 .83 to .98 <.001 
15 .94 .79 to .98 <.001 
16 .94 .86 to .97 <.001 
17 .96 .87 to .99 <.001 
18 .96 .86 to .99 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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Part II: Algometry 
 
Control Group Comparison 
 
 
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
 
 
 
 
 
 
 
 
 
 
 
 
 110 
 
Control Group Algometry: PPTS compared to MTPS 
Points Spearman rho 95% CI Correlation p-value 
1 .91 .75 to .96 <.001 
2 .92 .70 to .99 <.001 
3 .97 .89 to 1.0 <.001 
4 .98 .92 to 1.0 <.001 
5 .99 .95 to 1.0 <.001 
6 .99 .96 to 1.0 <.001 
7 .99 .98 to 1.0 <.001 
8 .99 .97 to 1.0 <.001 
9 .90 .67 to .97 <.001 
10 .88 .69 to .98 <.001 
11 .96 .87 to .99 <.001 
12 .97 .88 to .99 <.001 
13 .97 .92 to 99 <.001 
14 .97 .91 to 1.0 <.001 
15 .99 .97 to 1.0 <.001 
16 .99 .98 to 1.0 <.001 
17 .98 .92 to 1.0 <.001 
18 .99 .96 to 1.0 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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FM Group Comparison 
 
 
  
 
 
 
Descriptive Data: 18 points (Group n=28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
 
FM Group Algometry: PPTS compared to MTPS 
Points Spearman rho 95% CI Correlation p-value 
1 .79 .45 to .95 <.001 
2 .78 .34 to .95 <.001 
3 .83 .35 to .98 <.001 
4 .85 .70 to .94 <.001 
5 .85 .60 to .94 <.001 
6 .87 .60 to .96 <.001 
7 .94 .85 to .97 <.001 
8 .92 .80 to .97 <.001 
9 .68 .31 to .91 <.001 
10 .74 .52 to .90 <.001 
11 .82 .61 to .90 <.001 
12 .75 .47 to .93 <.001 
13 .86 .67 to .95 <.001 
14 .83 .63 to .96 <.001 
15 .91 .85 to .96 <.001 
16 .85 .63 to .91 <.001 
17 .71 .17 to .96 <.001 
18 .78 .54 to .96 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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MPS Group Comparison 
 
 
  
 
 
 
Descriptive Data: 18 points (Group n=28) 
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MPS Group Algometry: PPTS compared to MTPS 
Points Spearman rho 95% CI Correlation p-value 
1 .79 .39 to .96 <.001 
2 .78 .35 to .95 <.001 
3 .83 .50 to .97 <.001 
4 .85 .61 to .94 <.001 
5 .85 .65 to .94 <.001 
6 .87 .57 to .95 <.001 
7 .94 .87 to .97 <.001 
8 .92 .84 to .98 <.001 
9 .68 .28 to .92 <.001 
10 .74 .50 to .94 <.001 
11 .82 .52 to .92 <.001 
12 .75 .10 to .96 <.001 
13 .86 .70 to .95 <.001 
14 .83 .63 to .95 <.001 
15 .91 .77 to .96 <.001 
16 .86 .65 to .92 <.001 
17 .71 .28 to .96 <.001 
18 .78 .48 to .96 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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Appendix J 
 
 
 
 
 
 
Aim #4: Does manual palpation pressure up to 4 kg/cm2 measured by the 
Tekscan® digital pressure sensor at 18 predetermined tender points produce a 
comparable response by the participant as algometry pressure up to 4 kg/cm2 
using the 5-point PPTS in participants with MPS, FM, and in healthy 
individuals (control group)?  
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Part I: Manual Palpation with Pressure Sensor 
 
Control Group Comparison 
 
 
  
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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Control Group: Digital Pressure Sensor compared to Algometer  
Points Spearman rho 95% CI Correlation p-value 
1 .69 .39 to .84 <.001 
2 .70 .49 to .94 <.001 
3 .86 .64 to 1.0 <.001 
4 .82 .61 to 1.0 <.001 
5 .61 .16 to .90 .001 
6 .83 .52 to 1.0 <.001 
7 .42 .10 to .79 .03 
8 .85 .47 to 1.0 <.001 
9 .77 .57 to .90 <.001 
10 .77 .63 to .95 <.001 
11 .73 .46 to .92 <.001 
12 .74 .52 to .87 <.001 
13 .69 .41 to .99 <.001 
14 .48 .23 to .77 .01 
15 .41 .26 to .84 .03 
16 .99 .98 to 1.0 <.001 
17 .78 .50 to 1.0 <.001 
18 .76 .42 to 1.0 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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FM Group Comparison 
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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FM Group: Digital Pressure Sensor compared to Algometer  
Points Spearman rho 95% CI Correlation p-value 
1 .60 .38 to .78 .001 
2 .88 .76 to .96 <.001 
3 .74 .50 to .88 <.001 
4 .67 .28 to .81 <.001 
5 .69 .37 to .89 <.001 
6 .74 .43 to .92 <.001 
7 .75 .53 to .89 <.001 
8 .70 .37 to .91 <.001 
9 .85 .70 to .97 <.001 
10 .73 .55 to .89 <.001 
11 .90 .66 to .1.0 <.001 
12 .65 .39 to .90 <.001 
13 .59 .16 to .82 .001 
14 .50 .17 to .72 .009 
15 .80 .58 to .95 <.001 
16 .82 .56 to .91 <.001 
17 .59 .32 to .86 .001 
18 .72  .34 to .91 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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MPS Group Comparison 
 
 
 
 
 
Descriptive Data: 18 points (Group n=28) 
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MPS Group: Digital Pressure Sensor compared to Algometer  
Points Spearman rho 95% CI Correlation p-value 
1 .85 .68 to .94 <.001 
2 .77 .45 to .92 <.001 
3 .83 .70 to .94 <.001 
4 .85 .69 to .94 <.001 
5 .82 .65 to .91 <.001 
6 .66 .51 to .82 <.001 
7 .88 .72 to .99 <.001 
8 .82 .64 to .97 <.001 
9 .83 .59 to .96 <.001 
10 .63 .28 to .83 <.001 
11 .59 .14 to .85 <.001 
12 .78 .43 to .93 <.001 
13 .68 .38 to .87 <.001 
14 .70  .36 to .90 <.001 
15 .66 .44 to .83 <.001 
16 .84 .74 to .91 <.001 
17 .81 .63 to .91 <.001 
18 .76 .60 to .93 <.001 
CI: Confidence Interval; Statistically significant p<.05 
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